Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.

The pulmonary arterial hypertension (PAH) drug preserved its safety profile at 2.5 years of treatment and continued to reduce mortality compared with placebo.

Findings from surveys of women with pulmonary arterial hypertension (PAH) include that 20% of health care providers were viewed as dismissive because of the patient’s sex.

Cardiac output and stroke volume as measured by impedance cardiography may hold potential to predict clinical deterioration from pulmonary arterial hypertension (PAH).

The 18-meter walk test (18MWT) effectively evaluates disease severity and predicts clinical outcomes in pulmonary arterial hypertension (PAH), enhancing traditional assessment methods.

Medicaid beneficiaries face higher rates of pulmonary hypertension, with significant economic burdens and racial disparities in prevalence and costs.